146 related articles for article (PubMed ID: 17317654)
1. The X-linked adrenoleukodystrophy (X-ALD) and oxidative stress.
Al-Omar MA
J Herb Pharmacother; 2006; 6(3-4):125-34. PubMed ID: 17317654
[TBL] [Abstract][Full Text] [Related]
2. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
3. Lorenzo's oil may help to prevent ALD symptoms.
Senior K
Lancet Neurol; 2002 Dec; 1(8):468. PubMed ID: 12849323
[No Abstract] [Full Text] [Related]
4. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
5. Therapy of X-linked adrenoleukodystrophy.
Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
[TBL] [Abstract][Full Text] [Related]
6. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
Moser HW; Moser AB; Hollandsworth K; Brereton NH; Raymond GV
J Mol Neurosci; 2007 Sep; 33(1):105-13. PubMed ID: 17901554
[TBL] [Abstract][Full Text] [Related]
7. Therapy of X-linked adrenoleukodystrophy.
Moser HW
NeuroRx; 2006 Apr; 3(2):246-53. PubMed ID: 16554262
[TBL] [Abstract][Full Text] [Related]
8. Dietary treatment for X-linked adrenoleukodystrophy: is "Lorenzo's oil" useful?
Prieto Tenreiro A; Penacho Lázaro MÁ; Andrés Celda R; Fernández Fernández M; González Mateo C; Díez Hernández A
Endocrinol Nutr; 2013 Jan; 60(1):37-9. PubMed ID: 22622158
[No Abstract] [Full Text] [Related]
9. Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome.
Moser HW
J Inherit Metab Dis; 1995; 18(4):435-47. PubMed ID: 7494402
[TBL] [Abstract][Full Text] [Related]
10. Adrenoleukodystrophy and the mitochondrial connection: clues for supplementing Lorenzo's oil.
Moraes CT
Brain; 2013 Aug; 136(Pt 8):2339-41. PubMed ID: 23842565
[No Abstract] [Full Text] [Related]
11. Treatment of X-linked adrenoleukodystrophy with Lorenzo's oil.
Moser HW
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):279-80. PubMed ID: 10449544
[No Abstract] [Full Text] [Related]
12. Normal natural killer cell activity in a patient with adrenoleukodystrophy treated with Lorenzo's oil.
Tanaka M; Koike R; Kuwabara T
Neurodegeneration; 1996 Jun; 5(2):192-4. PubMed ID: 8819141
[No Abstract] [Full Text] [Related]
13. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
[TBL] [Abstract][Full Text] [Related]
14. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
[TBL] [Abstract][Full Text] [Related]
15. Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy.
Duchesne N; Dufour M; Bouchard G; Grondin P; Lemieux B
Can Assoc Radiol J; 1995 Oct; 46(5):386-91. PubMed ID: 7552831
[TBL] [Abstract][Full Text] [Related]
16. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
[TBL] [Abstract][Full Text] [Related]
17. Lorenzo's oil and lymphocytopenia.
Unkrig CJ; Schröder R; Scharf RE
N Engl J Med; 1994 Feb; 330(8):577. PubMed ID: 8204158
[No Abstract] [Full Text] [Related]
18. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
[TBL] [Abstract][Full Text] [Related]
19. Lorenzo's oil: a reassessment.
Poulos A; Robertson EF
Med J Aust; 1994 Mar; 160(6):315-7. PubMed ID: 8133809
[No Abstract] [Full Text] [Related]
20. Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.
Deon M; Garcia MP; Sitta A; Barschak AG; Coelho DM; Schimit GO; Pigatto M; Jardim LB; Wajner M; Giugliani R; Vargas CR
Metab Brain Dis; 2008 Mar; 23(1):43-9. PubMed ID: 18026827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
